<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398670</url>
  </required_header>
  <id_info>
    <org_study_id>P3-LIS-IMSFDA-01</org_study_id>
    <nct_id>NCT01398670</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics</brief_title>
  <official_title>Comparison of the Immunogenicity of Wockhardt's Insulin Analogue Lispro and Lispro Mix With Eli Lilly's Insulin Analogue Humalog® and Humalog® Mix in Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel group comparison of the immunogenicity safety of Wockhardt's
      Insulin analogue Lispro and lispro Mix with Eli Lilly's Insulin analogue Humalog® and
      Humalog® Mix in patients with Type 1 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate and compare the Immunogenicity safety of Wockhardt's Insulin analogue Lispro and
      lispro Mix with Eli Lilly's Insulin analogue Humalog® and Humalog® Mix in Type I Diabetic
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not initiated
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the immunogenic response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the immunogenicity with hypoglycemia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type I Diabetes</condition>
  <arm_group>
    <arm_group_label>Lispro arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lispro and Lispro Mix 75/25 /Lispro Mix 50/50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50
The drugs would be administered subcutaneously</description>
    <arm_group_label>Lispro arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50
The drugs would be administered subcutaneously</description>
    <arm_group_label>Humalog® arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who understand the nature of the study and are willing to provide written
             informed consent.

          2. Patients who have been pre-diagnosed as cases of type-1 diabetes for a period not less
             than 1 year

          3. Male or Female Patients ≥ 18 and &lt; 55 years of age.

          4. Patients with body mass index (BMI) of 18.0 to 30.0 kg/m2

          5. Patients who are cooperative, reliable, and agree to have regular injections of
             insulin and are willing to comply with protocol procedures.

          6. Ability to use the self glucose-monitoring device and to self inject insulin.

        Exclusion Criteria:

          1. Females who are pregnant or lactating, or not practicing adequate contraception.

          2. A Patient with compromised hepatic or renal function

          3. A Patient who is an employee of the Investigator, or a patient who has a direct
             involvement with the trial or other trials under the direction of the Investigator.

          4. A Patient who has been treated with other investigational agent or devices within the
             previous 30 days, has planned use of investigational drugs or devices, or has been
             previously randomized in this trial.

          5. A Patient with history or evidence of allergy to insulin preparations.

          6. A Patients who is currently receiving or has received, within the last year, any
             immunomodulator medications.

          7. Patients unlikely to comply with the study protocol e.g. unable to return periodically
             for subsequent visits.

          8. Patients who are judged by the investigator as inappropriate to participate in the
             study for any reason other than those mentioned.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Rasendrakumar Jha</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Diabetes</keyword>
  <keyword>Wockhardt's Insulin analogue Lispro</keyword>
  <keyword>Humalog®</keyword>
  <keyword>Humalog Mix</keyword>
  <keyword>Wockhardt</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

